Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies
AbstractBackgroundOcular inflammatory diseases, including scleritis and uveitis, have been widely treated with immunomodulatory therapies (IMTs) as a steroid-sparing approach. Such strategy includes conventional therapies (antimetabolites, alkylating agents, and calcineurin inhibitors) as well as biologic agents like adalimumab, infliximab, rituximab, and tocilizumab. Cyclophosphamide (CP) is an alkylating agent and mainly inhibits the functioning of both T and B cells. Though known to have potential adverse events, including bone marrow suppression, hemorrhagic cystitis, and sterility, CP has been shown to be efficacious,...
Source: Journal of Ophthalmic Inflammation and Infection - March 11, 2024 Category: Opthalmology Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
AbstractAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with pediatric patients were included in this review. Commonly used therapies, including ...
Source: Pediatric Drugs - March 11, 2024 Category: Pediatrics Source Type: research
Burkitt lymphoma: The effect of age, sex and delay to diagnosis on treatment completion and outcome of treatment in 934 Patients in Cameroon
This study analysed these factors in 934 patients with BL who had received cyclophosphamide and intrathecal methotrexate as treatment. MethodsRecords of 934 children diagnosed with BL from 2004 to 2015 were obtained from our Paediatric Oncology Networked Database (POND) cancer registry. Age at diagnosis, sex, disease stage, time to diagnosis, delay in diagnosis, completion of treatment, rate of abandonment, and one-year survival rates were recorded and statistically analysed. ResultsThe male to female ratio of 1.41 for the study population of 934. The median delay from onset of symptoms to diagnosis was 31 days. The St Jud...
Source: PLoS One - March 11, 2024 Category: Biomedical Science Authors: Peter Bernard Hesseling Source Type: research
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis
Br J Dermatol. 2024 Mar 8:ljae096. doi: 10.1093/bjd/ljae096. Online ahead of print.NO ABSTRACTPMID:38454565 | DOI:10.1093/bjd/ljae096 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 8, 2024 Category: Dermatology Authors: Amelle G Ra Zoe Littlewood Anne Barton Brian Keevil Malcolm McTaggart Richard B Warren James Bluett Source Type: research
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis
Br J Dermatol. 2024 Mar 8:ljae096. doi: 10.1093/bjd/ljae096. Online ahead of print.NO ABSTRACTPMID:38454565 | DOI:10.1093/bjd/ljae096 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 8, 2024 Category: Dermatology Authors: Amelle G Ra Zoe Littlewood Anne Barton Brian Keevil Malcolm McTaggart Richard B Warren James Bluett Source Type: research
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis
Br J Dermatol. 2024 Mar 8:ljae096. doi: 10.1093/bjd/ljae096. Online ahead of print.NO ABSTRACTPMID:38454565 | DOI:10.1093/bjd/ljae096 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 8, 2024 Category: Dermatology Authors: Amelle G Ra Zoe Littlewood Anne Barton Brian Keevil Malcolm McTaggart Richard B Warren James Bluett Source Type: research
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
ConclusionsThis real-world US cohort analysis described patients with PsA newly initiating tofacitinib; most were bDMARD-experienced or receiving monotherapy treatment. In patients who remained on therapy (48.8%), tofacitinib was effective across multiple PsA domains at 6 ± 3 months. Limitations included small patient numbers at follow-up and potential selection bias.Trial RegistrationClinicalTrials.gov identifier, NCT05195814. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 8, 2024 Category: Rheumatology Source Type: research
An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation
DiscussionThese case studies and our previous experience suggest that to achieve an effective reduction of anti-rhGAA antibodies in the setting of HSAT, bortezomib should be initiated at the earliest sign of high anti-rhGAA antibodies with a minimum of two consecutive cycles as shown in the case of patient 8. It is important to note that, despite initiation of ERT at age 2.3 weeks, patient 8 quickly developed HSAT. We recommend close monitoring of anti-rhGAA antibodies and early intervention with ITI as soon as significantly elevated anti-rhGAA antibody titers are noted. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 8, 2024 Category: Allergy & Immunology Source Type: research
Case report: Metastatic choriocarcinoma in the second trimester of a viable pregnancy with successful delivery and outcome after chemotherapy
Metastatic choriocarcinoma during viable pregnancy is rare worldwide, and neonate survival following pregnancy termination in the second trimester is uncommon. Here, we report the successful delivery of a pregnancy by a patient with metastatic choriocarcinoma, who received three courses of etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA-CO) chemotherapy in the second trimester. After multidisciplinary discussions, she was administered paclitaxel and carboplatin (TC) chemotherapy. Regular contractions occurred during her first paclitaxel infusion, and a healthy infant was delivered by cesarean...
Source: Frontiers in Oncology - March 8, 2024 Category: Cancer & Oncology Source Type: research
Molecules, Vol. 29, Pages 1189: Synthesis and Antioxidant Activities of Novel Pyrimidine Acrylamides as Inhibitors of Lipoxygenase: Molecular Modeling and In Silico Physicochemical Studies
iki
The pyrimidine ring is present in various biomolecules such as DNA and RNA bases, aminoacids, vitamins, etc. Additionally, many clinically used drugs including methotrexate and risperidone contain the pyrimidine heterocyclic scaffold as well. Pyrimidine derivatives present diverse biological activities including antioxidant and anticancer activities and can be considered as privileged scaffolds in drug discovery for the treatment of various diseases. Piperidine pyrimidine amides have gained significant attention due to their enzymatic inhibitory activity. Based on our experience and ongoing investigation on cinnami...
Source: Molecules - March 7, 2024 Category: Chemistry Authors: Michail Saragatsis Eleni Pontiki Tags: Article Source Type: research
Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons
Expert Rev Clin Immunol. 2024 Mar 6:1-16. doi: 10.1080/1744666X.2024.2326628. Online ahead of print.ABSTRACTINTRODUCTION: ANCA-associated vasculitides (AAV), classified into granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis represent a group of disorders characterized by necrotizing vasculitis of small vessels, endothelial injury and tissue damage. The outcomes and prognosis of AAV have undergone significant changes with the introduction of glucocorticoids (GCs) and other immunosuppressants (cyclophosphamide, azathioprine, methotrexate, and mycophenolate mofetil)....
Source: Expert Review of Clinical Immunology - March 6, 2024 Category: Allergy & Immunology Authors: Francesco Reggiani Matteo Stella Marta Calatroni Renato Alberto Sinico Source Type: research
International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector
(Source: Patient Preference and Adherence)
Source: Patient Preference and Adherence - March 5, 2024 Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice
We report the case of a patient with severe AD and inadequate response to upadacitinib who showed a complete response after switching to abrocitinib. A 23-year-old male patient with severe AD was enrolled in the Measure Up double-blind, placebo-controlled, phase 3 randomized clinical trial. At baseline, the Eczema Area Severity Index (EASI) was 50.6, the Investigator's Global Assessment (IGA) was 4, the affected Body Surface Area (BSA) was 80%, and the Worst Pruritus-Numeric Rating Scale (WP-NRS) was 10/10 (Figure 1). At week 124, the patient discontinued participation in the trial, while EASI was 9.2, IGA 3, BSA 20%, and ...
Source: Herpes - March 5, 2024 Category: Infectious Diseases Authors: Styliani Mastraftsi Michail Bakakis Aikaterini Tsiogka Ileana Afroditi Kleidona Stamatios Gregoriou Source Type: research
How can we optimize the use of methotrexate to treat pediatric patients with inflammatory skin diseases?
. (Source: Expert Opinion on Drug Metabolism and Toxicology)
Source: Expert Opinion on Drug Metabolism and Toxicology - March 4, 2024 Category: Drugs & Pharmacology Authors: Kajetan Kie łbowskiEstera BakinowskaAndrzej PawlikDepartment of Physiology, Pomeranian Medical University, Szczecin, Poland Source Type: research
